(biopharmaceutical, Boston) has been up 33.02% YoY, several earnings beats and FDA approvals recently.
I'm currently bullish on them based on FDA approvals on the pipeline on product and significant value investing opportunity at this stage.
Taken below quick notes in each business indicator:
Financials: In 2023, EBITDA reached $4 billion, with revenue hitting $9.87 billion and a $13.7 billion net cash position.
Growth: 2023 revenue rose by 11%, with a projected 8% increase in 2024.
Product: Trikafta/Kaftrio earned $6.04 billion in the U.S. and $3.83 billion internationally in 2023, treating cystic fibrosis.
Pipeline: Casgevy for sickle cell disease received approvals in multiple regions in 2023.
Valuation: Vertex's enterprise value stands at $101.38 billion, with an EBITDA multiple of 25.4.
My outlook is that it's a company with solid finances and promising products, offers potential in the biotech sector.